Biological markers: Potential biomarker for aspirin use in colorectal cancer therapy

Nature Reviews Clinical Oncology

Volumn 10, Issue 1, 2013, Pages 8-10

  Langley, Ruth E ^a   Rothwell, Peter M ^b  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

CANCER THERAPY; COLORECTAL CANCER; DISTANT METASTASIS; DOSE RESPONSE; DRUG MECHANISM; DRUG USE; GENE FREQUENCY; HUMAN; LOW DRUG DOSE; MUTATOR GENE; NONHUMAN; NOTE; OVERALL SURVIVAL; PATIENT SELECTION; PERSONALIZED MEDICINE; PIK3CA GENE; PRIORITY JOURNAL; ARTICLE; COLORECTAL TUMOR; GENETICS; MORTALITY; MUTATION; PROGNOSIS; SURVIVAL RATE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLORECTAL NEOPLASMS; HUMANS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84871623952     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.216     Document Type: Note

References (10)

1. Langley, R. E. et al. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br. J. Cancer 105, 1107-1113 (2011).
2. Rothwell, P. M. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376, 1741-1750 (2010).
3. Rothwell, P. M. et al. Long-term effect of aspirin on deaths due to cancer: pooled analysis of data from randomised controlled trials. Lancet 377, 31-41 (2011).
4. Rothwell, P. M. et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379, 1602-1612 (2012).
5. Burn, J. et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378, 2081-2087 (2012).
6. Rothwell, P. M. et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379, 1591-1601 (2012).
7. Chan, A. T., Ogino, S. & Fuchs, C. S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302, 649-658 (2009).
8. Liao, X. et al. Aspirin use, tumour PIK3CA mutation and colorectal-cancer survival. N. Engl. J. Med. 367, 1596-1606 (2012).
9. Thun, M. J., Jacobs, E. J. & Patrono, C. The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol. 9, 259-267 (2012).
10. Holmes, M. D. et al. COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res. Treat. 130, 657-662 (2011).